Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600 mg BID dose selection in a crizotinib-progressed or intolerant population

MLA

Ronan Carnac, et al. “Population Pharmacokinetics (PopPK) and Exposure-Response (ER) Analyses to Confirm Alectinib 600 Mg BID Dose Selection in a Crizotinib-Progressed or Intolerant Population.” Journal of Clinical Oncology, vol. 34, May 2016, p. e20598. EBSCOhost, https://doi.org/10.1200/jco.2016.34.15_suppl.e20598.

APA

Ronan Carnac, Elena Guerini, Bogdana Balas, Joy C. Hsu, Ali Zeaiter, Volkmar Henschel, Meret Martin-Facklam, Peter N. Morcos, Alex Phipps, Katrijn Bogman, & Nicolas Frey. (2016). Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600 mg BID dose selection in a crizotinib-progressed or intolerant population. Journal of Clinical Oncology, 34, e20598. https://doi.org/10.1200/jco.2016.34.15_suppl.e20598

Chicago

Ronan Carnac, Elena Guerini, Bogdana Balas, Joy C. Hsu, Ali Zeaiter, Volkmar Henschel, Meret Martin-Facklam, et al. 2016. “Population Pharmacokinetics (PopPK) and Exposure-Response (ER) Analyses to Confirm Alectinib 600 Mg BID Dose Selection in a Crizotinib-Progressed or Intolerant Population.” Journal of Clinical Oncology 34 (May): e20598. doi:10.1200/jco.2016.34.15_suppl.e20598.